Literature DB >> 16839923

Effect of energy substrate manipulation on tumour cell proliferation in parenterally fed cancer patients.

F Rossi-Fanelli1, F Franchi, M Mulieri, C Cangiano, A Cascino, F Ceci, M Muscaritoli, P Seminara, L Bonomo.   

Abstract

The effects of isocaloric carbohydrate-based vs. fat-based total parenteral nutrition (TPN) regimens on cancer cell proliferation and host nutritional status were evaluated in 27 patients with tumours of the gastro intestinal tract consecutively assigned to receive for 14 days: a glucose-based (A) or a lipid-based (B) TPN formula, or an oral diet (C) isocaloric and isonitrogenous to A and B. Cancer cell replication rate was evaluated by thymidine labelling index (LI) on tumour samples before and at the end of each nutritional regimen. The number of replicating cells increased by 32.2% in patients receiving regimen A. LI decreased by 24.3% in patients given regimen B. LI values were slightly increased (+15%) in patients maintained on regimen C. Nutritional status remained within normal limits. None of the LI changes observed between and within the three arms of the trial were found to be statistically significant. Thus we failed to prove that glucose consistently stimulates or lipids inhibit tumour proliferation despite a trend in this sense.

Entities:  

Year:  1991        PMID: 16839923     DOI: 10.1016/0261-5614(91)90043-c

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  14 in total

1.  [Efficacy of a ketogenic diet in urological cancers patients : A systematic review].

Authors:  P Maisch; J E Gschwend; M Retz
Journal:  Urologe A       Date:  2018-03       Impact factor: 0.639

Review 2.  Systematic review: isocaloric ketogenic dietary regimes for cancer patients.

Authors:  N Erickson; A Boscheri; B Linke; J Huebner
Journal:  Med Oncol       Date:  2017-03-28       Impact factor: 3.064

Review 3.  Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review.

Authors:  Vicente Javier Clemente-Suárez; Laura Redondo-Flórez; Alejandro Rubio-Zarapuz; Ismael Martínez-Guardado; Eduardo Navarro-Jiménez; José Francisco Tornero-Aguilera
Journal:  Int J Environ Res Public Health       Date:  2022-04-11       Impact factor: 4.614

4.  The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer.

Authors:  Angela M Poff; Csilla Ari; Thomas N Seyfried; Dominic P D'Agostino
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

5.  Is there a role for carbohydrate restriction in the treatment and prevention of cancer?

Authors:  Rainer J Klement; Ulrike Kämmerer
Journal:  Nutr Metab (Lond)       Date:  2011-10-26       Impact factor: 4.169

Review 6.  Restricting carbohydrates to fight head and neck cancer-is this realistic?

Authors:  Rainer J Klement
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

7.  Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer.

Authors:  A M Poff; C Ari; P Arnold; T N Seyfried; D P D'Agostino
Journal:  Int J Cancer       Date:  2014-05-14       Impact factor: 7.396

Review 8.  Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.

Authors:  R J Klement; M K Fink
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

9.  The ketogenic diet is not feasible as a therapy in a CD-1 nu/nu mouse model of renal cell carcinoma with features of Stauffer's syndrome.

Authors:  Silvia Vidali; Sepideh Aminzadeh-Gohari; René Günther Feichtinger; Renaud Vatrinet; Andreas Koller; Felix Locker; Tricia Rutherford; Maura O'Donnell; Andrea Stöger-Kleiber; Bridget Lambert; Thomas Klaus Felder; Wolfgang Sperl; Barbara Kofler
Journal:  Oncotarget       Date:  2017-07-17

Review 10.  Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation.

Authors:  Rainer J Klement; Colin E Champ
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.